Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle ...

CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping and its ... "As of January 23, 2025, all treatment related adverse events in CONNECT1 have ...

Paul Streck, MD, Head of R&D, commented, “As of January 23, 2025, all treatment related ... for the treatment of patients with DMD amenable to an exon-51 skipping approach.

today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for patients amenable to an exon-51 skipping approach.

Multiple companies are digging in to add the next generation of exon skippers, gene therapies and medicines targeting more than skeletal muscle to their DMD pipelines, and for Michael Kelly, chief ...

Some types of muscular dystrophy can be fatal. Certain types, including Duchenne muscular dystrophy, can lead to problems with the heart and muscles used for breathing. Some people with MD may develop ...